Get the Stockscreener App
5.27
4.01%
-0.22
Abeona Therapeutics Inc stock is traded at $5.27, with a volume of 1.15M.
It is down -4.01% in the last 24 hours and up +20.59% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
See More
Previous Close:
$5.49
Open:
$5.49
24h Volume:
1.15M
Relative Volume:
0.93
Market Cap:
$320.13M
Revenue:
-
Net Income/Loss:
$-54.19M
P/E Ratio:
-2.0426
EPS:
-2.58
Net Cash Flow:
$-37.34M
1W Performance:
-19.66%
1M Performance:
+20.59%
6M Performance:
-17.66%
1Y Performance:
+18.43%
1-Day Range:
$5.25
$5.57
1-Week Range:
$5.12
$6.6892
52-Week Range:
$3.9328
$7.3236
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.27 | 320.13M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ABEO Stock News - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
StockWatch: Second Time’s the Charm for Abeona’s Gene Therapy - Genetic Engineering and Biotechnology News
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease - MSN
Abeona Therapeutics (ABEO) Gains FDA Approval for Gene Therapy | ABEO Stock News - GuruFocus
Institutional investors control 44% of Abeona Therapeutics Inc. (NASDAQ:ABEO) and were rewarded last week after stock increased 22% - simplywall.st
FDA approves Abeona’s $3.1m cell therapy for rare skin disease - MSN
ABEO: Zevaskyn Approved by FDA Raising Valuation to 11 - Smartkarma
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease - Benzinga
Abeona Therapeutics (ABEO) Sees Price Target Boost Amid FDA Appr - GuruFocus
Abeona Stock Surges to 52-Week High: What's Behind The Move? - Benzinga
Abeona’s ZEVASKYN Gets FDA Nod for Rare Skin Disease - Contract Pharma
FDA approves Abeona’s Zevaskyn - The Pharma Letter
Abeona prices rare cell disorder gene therapy at $3.1m - Pharmaphorum
Historic achievement: FDA approval of Abeona Therapeutics' ZEVASKYN accelerates momentum and expands treatment options for the EB community. - Olean Times Herald
Stifel lifts Abeona stock target to $21, maintains buy rating By Investing.com - Investing.com Canada
Stifel lifts Abeona stock target to $21, maintains buy rating - Investing.com
FDA Approves Abeona Gene Therapy for Healing Wounds From Rare, Inherited Skin Disease - MedCity News
Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy - insights.citeline.com
Abeona cell therapy approved by FDA for rare skin condition - BioPharma Dive
Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy - Yahoo
Abeona Therapeutics (ABEO) Sees Price Target Boost Amid Zevaskyn - GuruFocus
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease By Stocktwits - Investing.com India
Cleveland company receives FDA approval for rare disease treatment - Crain's Cleveland Business
FDA Approval of Zevaskyn Boosts ABEO Prospects | ABEO Stock News - GuruFocus
Abeona’s rare skin disease gene therapy approved by FDA - BioWorld MedTech
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees - GuruFocus
Abeona Therapeutics Says US FDA Approves Zevaskyn to Treat Wounds in Patients With Genetic Skin Disease - marketscreener.com
US FDA approves first cell-based gene therapy for rare genetic skin disorder - Reuters
Abeona spikes on FDA nod for gene therapy - MSN
Abeona Therapeutics Hosts Conference Call and Webcast - TipRanks
FDA Greenlights Abeona Therapeutics' Gene Therapy Zevaskyn for R - GuruFocus
Abeona Therapeutics (ABEO) Jumps on FDA Nod for Gene Therapy Zev - GuruFocus
FDA Approves Abeona Therapeutics' Epidermolysis Bullosa Gene Therapy Pz-Cel - CGTLive®
Abeona stock gains on FDA nod for gene therapy (ABEO:NASDAQ) - Seeking Alpha
FDA Greenlights Abeona Therapeutics' Gene Therapy Zevaskyn for RDEB | ABEO Stock News - GuruFocus
US FDA approves Abeona's skin disorder therapy - marketscreener.com
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) - GlobeNewswire
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) - GlobeNewswire Inc.
Is Abeona Therapeutics Inc (NASDAQ: ABEO) Stock Poised for More Growth? - Marketing Sentinel
How did Abeona Therapeutics Inc (ABEO) fare last session? - uspostnews.com
Global Fanconi Anemia Market Insights: Jasper Therapeutics, - openPR.com
Gaining Ground: Abeona Therapeutics Inc (ABEO) Closes Lower at 4.84, Down -0.21 - DWinneX
Abeona Therapeutics Inc (ABEO) looking to reclaim success with recent performance - Sete News
ABEO Shares Experience Surge in Value - knoxdaily.com
Stock Performance Spotlight: Abeona Therapeutics Inc (ABEO) Ends the Day at 5.22, Down by -1.14 - DWinneX
Examining ABEO’s book value per share for the latest quarter - uspostnews.com
Why Invest In Abeona Therapeutics Inc (ABEO) Stock? - Marketing Sentinel
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):